

JAN 04 2005 2:18PM

BMS PATENT DEPT


NO. 3608 P. 5

In re Application of Lloyd et al.,  
S.N. 10/823,987  
Filed: 4/14/2004

# CLAIM AMENDMENTS

1-17. Cancelled.

18. (Currently amended) A compound having the structure



or pharmaceutically acceptable salts thereof, prodrug esters thereof, or all stereoisomers thereof, wherein

A, B and D are each -CH or N;

$\begin{matrix} R^3 \\ | \\ -(C) \\ | \\ R^4 \end{matrix}$   
X<sup>1</sup> is  $\begin{matrix} R^3 \\ | \\ -(C) \\ | \\ R^4 \end{matrix}$ , where n is 1, 2 or 3, and where R<sup>3</sup> and R<sup>4</sup> are independently H, alkyl, arylalkyl or cycloalkyl, or R<sup>3</sup> and R<sup>4</sup> can be taken together with the carbon to which they are attached to form a 5 to 8 carbon containing ring; and R<sup>5</sup> is H, alkyl, alkenyl, aryl, arylalkyl, cycloalkyl or cycloalkylalkyl;

R is H, alkyl, alkenyl, aryl, arylalkyl, heterocycloalkyl, cycloalkyl, or cycloalkylalkyl;

R<sup>1</sup> is alkyl, arylalkyl, aryl, alkenyl, heterocyclo, heterocycloalkyl,  $\begin{matrix} N-heterocycle \\ | \\ R^{5a} \end{matrix}$

(where R<sup>5a</sup> can be any of the R<sup>5</sup> groups), where R<sup>5a</sup> is selected from H, alkyl, alkenyl,

aryl, arylalkyl, cycloalkyl, cycloalkylalkyl or  $\begin{matrix} R^6 \\ | \\ N-R^7 \end{matrix}$  (where R<sup>6</sup> and R<sup>7</sup> are independently selected from H, aryl, alkyl, arylalkyl or cycloalkyl, or R<sup>6</sup> and R<sup>7</sup> can be taken together with the nitrogen atom to which they are attached to form a 5 to 8 membered ring); or R and R<sup>1</sup> can be taken together with the -N-S- atoms to form a 5- to 8-membered ring;

X<sup>2</sup> is a single bond,  $\begin{matrix} N \\ | \\ R^8 \end{matrix}$  or -O- (where R<sup>8</sup> is H, alkyl, alkenyl, aryl, arylalkyl,

cycloalkyl or cycloalkylalkyl);

R<sup>2</sup> is H, alkyl, arylalkyl,  $\begin{matrix} O \\ || \\ -C-alkyl \end{matrix}$ ,  $\begin{matrix} O \\ || \\ -C-arylalkyl \end{matrix}$ ,  $\begin{matrix} O \\ || \\ -CH_2-C-O-R^{10} \end{matrix}$  or

$\begin{matrix} O \\ || \\ -CH_2-C-N-R^{10} \\ | \\ R^{11} \end{matrix}$  (where R<sup>10</sup> and R<sup>11</sup> are independently selected from H, alkyl, arylalkyl or


In re Application of Lloyd et al.,  
S.N. 10/823,987  
Filed: 4/14/2004

cycloalkyl, or  $R^{10}$  and  $R^{11}$  can be taken together with the nitrogen to which they are attached to form a 5- to 8-membered ring); and


Q is  $R^{12}-\overset{\overset{X}{\parallel}}{\underset{\underset{NC-N}{\parallel}}{C}}-\overset{\overset{R^{15}}{\mid}}{N}-R^{16}$ , (where  $R^{12}$  is alkyl, arylalkyl, aryl,  $-N-R^{15}$ , heterocycle,

heterocycloalkyl, where  $R^{15}$  and  $R^{16}$  are independently selected from H, alkyl, arylalkyl, aryl, heterocycle, cycloalkyl, amino, aminoalkyl, or heterocycloalkyl, or  $R^{15}$  and  $R^{16}$  can be taken together with the nitrogen to which they are attached to form a 5- to 8-membered ring which may optionally contain an additional nitrogen atom in the ring and/or an amino group or an aminoalkyl group attached to the ring).


19. (Previously submitted) The compound as defined in Claim 18 having the structure



20. (Previously submitted) The compound as defined in Claim 18 having the structure



21. (Previously submitted) The compound as defined in Claim 18 having the structure



22. (Previously submitted) The compound as defined in Claim 18 wherein

R is H;


$R^1$  is aryl or alkyl;

$X^2$  is O or a single bond; and

$R^2$  is H.

In re Application of Lloyd et al.,  
S.N. 10/823,887  
Filed: 4/14/2004

23. (Previously submitted) A compound of claim 18:



24. (Previously submitted) A pharmaceutical composition comprising a compound as defined in Claim 18 in combination with one or more components selected from the group consisting of cyclooxygenase inhibitors, fibrinogen antagonists, diuretics, angiotensin converting enzyme inhibitors, angiotensin II antagonists, thrombolytic agents, calcium channel blocking agents, thromboxane receptor antagonists, prostacyclin mimetics and phosphodiesterase inhibitors.